Recruiting Pulmonary Hypertension Studies in Hamilton
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Terminat...
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an ex...
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts: * Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants wit...
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis....
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
The purpose of this study is to assess the risk of bleeding due to failure of expected pharmacological action of CSL222 in adults with severe or moderately severe hemophilia B with detectable pretreat...
About Pulmonary Hypertension Clinical Trials in Hamilton
Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.
There are currently 5 pulmonary hypertension clinical trials recruiting participants in Hamilton, ONTARIO. These studies are seeking a combined 515 participants. Research is being sponsored by Pfizer, Regeneron Pharmaceuticals, Hoffmann-La Roche and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Hypertension Clinical Trials in Hamilton — FAQ
Are there pulmonary hypertension clinical trials in Hamilton?
Yes, there are 5 pulmonary hypertension clinical trials currently recruiting in Hamilton, ONTARIO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Hamilton?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hamilton research site will contact you about next steps.
Are clinical trials in Hamilton free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hamilton studies also compensate for your time and travel.
What pulmonary hypertension treatments are being tested?
The 5 active trials in Hamilton are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.
Data updated March 2, 2026 from ClinicalTrials.gov